CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

  • CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE\u00ae (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled